# E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

> **NCT01332266** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 95 (actual)

## Conditions studied

- Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** E7050
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01332266
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09-19
- **Primary completion:** 2016-01-31
- **Final completion:** 2017-09-04
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2022-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01332266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01332266, "E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01332266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*